Modular retro-vectors for transgenic and therapeutic use

Solaiman, Fauzia; Zink, Mary Ann; Xu, Guoping; Grunkemeyer, James A.; Cosgrove, Dominic; Saenz, Jennifer; Hodgson, Clague P.

doi:10.1002/(sici)1098-2795(200006)56:2+<309::aid-mrd22>3.0.co;2-y

Cited by 17 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retroviruses enter cells via specific receptors, following which viral RNA is reverse transcribed to DNA that is integrated into the cellular chromosomal architecture, leading to stable, prolonged and high expression of the therapeutic transgene [53][54][55]. Replication-deficient retroviruses are produced in vitro in specific packaging cell lines containing retroviral genes (G, P, E) that have been deleted from the retroviral genome.…”

Section: Viral Vectorsmentioning

confidence: 99%

“…Replication-deficient retroviruses are produced in vitro in specific packaging cell lines containing retroviral genes (G, P, E) that have been deleted from the retroviral genome. Retroviruses can only transduce dividing cells, thus limiting their target cell population [53][54][55]. The second limitation of retroviruses is their low titer.…”

Section: Viral Vectorsmentioning

confidence: 99%

See 1 more Smart Citation

Targeting vascular endothelial growth factor in angina therapy

Boodhwani

Ramlawi

Laham

et al. 2006

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Despite tremendous success of growth factor therapy in animal models, clinical trials have demonstrated minimal success. Vascular endothelial growth factors are perhaps the most potent inducers of angiogenesis in these animal models. This review outlines the biology of vascular endothelial growth factors in the context of myocardial angiogenesis with an emphasis on its effects on the endothelium. It also provides an overview of delivery strategies and summarises the preclinical and clinical evidence relating to exogenous growth factor delivery for myocardial angiogenesis with an emphasis on the key future challenges.

show abstract

Section: Viral Vectorsmentioning

confidence: 99%

Section: Viral Vectorsmentioning

confidence: 99%

Targeting vascular endothelial growth factor in angina therapy

Boodhwani

Ramlawi

Laham

et al. 2006

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

“…In the present study, a lentivirus-mediated RNAi technique was used to address the function of the MYCL1 gene in MGC-803 gastric cancer cells. 13,14 Our aim was to assess whether MYCL1 is a promising therapeutic target gene for gastric cancer. (100 U/mL), and streptomycin (100 μg/mL) and was incubated in a 5% CO 2 humidified incubator at 37°C.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 Our aim was to assess whether MYCL1 is a promising therapeutic target gene for gastric cancer. 13,14 Our aim was to assess whether MYCL1 is a promising therapeutic target gene for gastric cancer.…”

mentioning

confidence: 99%

Targeted silencing of MYCL1 by RNA interference inhibits migration and invasion of MGC‐803 gastric cancer cells

Pan

Wang

Zhang

et al. 2019

Cell Biochemistry & Function

View full text Add to dashboard Cite

MYCL1 protein expression encoded by a proto-oncogene MYCL1, a member of the MYC family, is correlated with poor prognosis in gastric cancer patients. Nevertheless, the role of MYCL1 in gastric cancer cells remains unknown. In this study, the expression levels of MYCL1 mRNA and protein were downregulated by lentiviral-mediated RNA interference (RNAi) in the MGC-803 gastric cancer cell line. Then, the influence of MYCL1 on the biological behaviour of gastric cancer cells was investigated. Finally, a stable animal model of the MGC-803 human gastric cancer tumour model in nude mice was made successfully. Functionally, silencing of MYCL1 inhibited migration and invasion of the MGC-803 line in vitro and was accompanied with some ultrastructural changes. These results provide some evidences that lentiviral-mediated MYCL1 silencing may be a novel therapeutic strategy for the treatment of gastric cancer.Significance of the study: Gastric cancer is one of the most common malignant tumours worldwide and the second leading cause of cancer-related death in China.Our previous study revealed that expression of MYCL1 in gastric cancer tissue was associated with poor prognosis of patients. However, the potential underlying mechanism is still unclear. In the current study, we displayed the influence of MYCL1 gene on invasion and migration phenotype of gastric cancer cells and provided a possible explanation from the aspect of structural alteration. Our results suggested that downregulation of MYCL1 may be a potential therapeutic strategy for gastric cancer. KEYWORDS gastric cancer, lentiviral-mediated RNAi, migration and invasion, MYCL1 1 | INTRODUCTION Gastric cancer is a common malignant tumour that is easily disseminated. Most patients are in the advanced stages when diagnosed, and 5-year survival rate is very low even if they had been given proper treatments. 1-3 Thus, strengthening the basic and clinical research of gastric cancer is very important. As a gene located on chromosome 1p34.2, MYCL1 is an important member of the MYC gene family and is considered to be a proto-oncogene. It plays important roles in regulating cell growth, differentiation, proliferation, apoptosis, and angiogenesis. 4 MYCL1 is amplified and overexpressed in a number of malignancies, including cancers of the ovary, nasopharynx, Merkel cell, liver, colorectal, In our previous case-control study, we found that one MYCL1 intronic single-nucleotide polymorphism (SNP), rs3134613, was associated with susceptibility to diffuse-type gastric cancer and with differentiation of gastric cancer. 11 In our more recent study, the expression of MYCL1 in gastric cancer tissue was detected by immunohistochemistry, and its clinical significance was analysed. We found that MYCL1 was more highly expressed in poorly differentiated and advanced Pan Qin and Haiyan Wang contributed equally to this work.

show abstract

“…The employment of some viral vectors is restricted by their limited capacity to carry foreign genes. Numerous strategies are currently under development to overcome safety risks and to improve targeting strategies of viral vectors2, 13–15.…”

Section: Introductionmentioning

confidence: 99%